A computational drug-design pipeline that targets G-quadruplex (G4) DNA structures in plants to develop novel herbicides with new modes of action. Uses molecular dynamics and free-energy calculations, validated against cancer drug benchmarks, to identify selective, non-toxic herbicidal compounds for agricultural applications.
This project proposes a computational platform for designing novel herbicides by targeting G-quadruplex (G4) DNA structures in plants. G-quadruplexes are four-stranded helical DNA folding motifs that regulate multiple biological processes and have been identified as a ubiquitous regulatory element in plants. By applying molecular dynamics (MD) simulations and free-energy calculations to study drug binding modes on these structures, the platform aims to identify compounds with new modes of action, offering improved efficiency, selectivity, and non-toxicity compared to existing herbicides.
Key features:
The underlying computational methodology has been validated through benchmarking against experimental FRET data for metallorganic cancer drug compounds, with predictions within 5 percent of measured values. The approach is now being extended from cancer drug applications to plant biology, requiring approximately one year of further development. Future work includes mapping the spectrum of G4 structures relevant in plants, integrating AI-driven toxicity prediction, and validating candidate herbicides experimentally. The team is seeking partners with herbicidal expertise, equipment support, and key personnel to advance the platform toward maturity.
Cardiff University is a comprehensive public research university in Wales with substantial research activity and a broad academic portfolio. An innovation campus and translational research hubs provide co-located laboratories, shared prototyping facilities, and space for industry partners and startups. Close integration with a major teaching hospital enables clinical trials, regulatory engagement, and access to diverse patient populations. Research is backed by UK Research and Innovation councils, national health research funders, and competitive philanthropic and government sources. A dedicated technology transfer office supports IP management, licensing, sponsored research agreements, and new venture creation.